Anne E Lykkesfeldt1, Benedikte R Iversen2, Maj-Britt Jensen3, Bent Ejlertsen3, Anita Giobbie-Hurder4, Birgit E Reiter1, Tove Kirkegaard5, Birgitte B Rasmussen2. 1. a Unit of Cell Death and Metabolism , Danish Cancer Society Research Center , Copenhagen , Denmark. 2. b Department of Pathology , Herlev University Hospital , Herlev , Denmark. 3. c Danish Breast Cancer Cooperative Group (DBCG) , Rigshospitalet , Copenhagen , Denmark. 4. d International Breast Cancer Study Group (IBCSG), Department of Biostatistics & Computational Biology , Dana-Farber Cancer Institute , Boston , MA , USA. 5. e Department of Surgery , Zealand University Hospital , Koege , Denmark.
Abstract
BACKGROUND: Cell culture studies have disclosed that the mitotic Aurora kinase A is causally involved in both tamoxifen and aromatase inhibitor resistant cell growth and thus may be a potential new marker for endocrine resistance in the clinical setting. MATERIAL AND METHODS: Archival tumor tissue was available from 1323 Danish patients with estrogen receptor (ER) positive primary breast cancer, who participated in the Breast International Group (BIG) 1-98 trial, comparing treatment with tamoxifen and letrozole and both in a sequence. The expression of Aurora A was determined by immunohistochemistry in 980 tumors and semi quantitively scored into three groups; negative/weak, moderate and high. The Aurora A expression levels were compared to other clinico-pathological parameters and outcome, defined as disease-free survival (DFS) and overall survival (OS). RESULTS:High expression of Aurora A was found in 26.9% of patients and moderate in 57.0%. High expression was significantly associated with high malignancy grade and HER2 amplification. High Aurora A expression was significantly more frequent in ductal compared to lobular carcinomas. We found no significant association between Aurora A expression and DFS or OS and no evidence of interaction between Aurora A expression and benefits from tamoxifen versus letrozole. CONCLUSIONS: Aurora A expression in breast tumors was associated with high malignancy grade III and with HER2 amplification. A trend as a prognostic factor for OS was found in patients with high Aurora A expression. No predictive property was observed in this study with early breast cancer.
RCT Entities:
BACKGROUND: Cell culture studies have disclosed that the mitotic Aurora kinase A is causally involved in both tamoxifen and aromatase inhibitor resistant cell growth and thus may be a potential new marker for endocrine resistance in the clinical setting. MATERIAL AND METHODS: Archival tumor tissue was available from 1323 Danish patients with estrogen receptor (ER) positive primary breast cancer, who participated in the Breast International Group (BIG) 1-98 trial, comparing treatment with tamoxifen and letrozole and both in a sequence. The expression of Aurora A was determined by immunohistochemistry in 980 tumors and semi quantitively scored into three groups; negative/weak, moderate and high. The Aurora A expression levels were compared to other clinico-pathological parameters and outcome, defined as disease-free survival (DFS) and overall survival (OS). RESULTS: High expression of Aurora A was found in 26.9% of patients and moderate in 57.0%. High expression was significantly associated with high malignancy grade and HER2 amplification. High Aurora A expression was significantly more frequent in ductal compared to lobular carcinomas. We found no significant association between Aurora A expression and DFS or OS and no evidence of interaction between Aurora A expression and benefits from tamoxifen versus letrozole. CONCLUSIONS:Aurora A expression in breast tumors was associated with high malignancy grade III and with HER2 amplification. A trend as a prognostic factor for OS was found in patients with high Aurora A expression. No predictive property was observed in this study with early breast cancer.
Authors: Li Wang; Jialin Qu; Yu Liang; Deze Zhao; Faisal Ul Rehman; Kang Qin; Xiaochun Zhang Journal: Thorac Cancer Date: 2020-02-14 Impact factor: 3.500
Authors: Po-Jen Yang; Ming-Ju Hsieh; Chun-I Lee; Chi-Hua Yen; Hsiang-Ling Wang; Whei-Ling Chiang; Tu-Chen Liu; Thomas Chang-Yao Tsao; Chia-Yi Lee; Shun-Fa Yang Journal: Int J Environ Res Public Health Date: 2020-10-08 Impact factor: 3.390